RPL11 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 201 amino acids (1-178) and having a molecular mass of 22.6kDa.RPL11 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
RPL11 Human
目录号: GP24413纯度: >98%
Ribosomal Protein L11 Human Recombinant
| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 5μg | ¥840.00 | 现货 | 1 | |
| 20μg | ¥2,030.00 | 现货 | 1 | |
| 1mg | ¥37,800.00 | 现货 | 1 |
电话: 400-920-5774Email: sales@glpbio.cn
文献被引
本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
Nature641, 529–536 (2025)
Nature628, 630–638 (2024)
Nature632, 686–694 (2024)
Nature618, 1017–1023 (2023)
Nature610, 366–372 (2022)
Cell187(9):2288-2304 (2024)
Cell183(7):1867-1883 (2020)
Science388(6745) (2025)
Science387(6739) (2025)
Science387(6734) (2025)
Cell Research35, 97–116 (2025)
Cell Research34, 683–706 (2024)
Cell Research33, 273–287 (2023)
Cell Research33, 546–561 (2023)
Cell Research33, 904–922 (2023)
Cell Research31, 1291–1307 (2021)
产品描述 Description
产品文档 Product Documents
Purity:>98%
Product Data
Purity
Greater than 90% as determined by SDS-PAGE.
Source
Escherichia Coli.
Physical Appearance
Sterile Filtered clear solution.
Shipping Condition
Shipped with Ice Packs.
Synonyms
Ribosomal Protein L11; Cell Growth-Inhibiting Protein 34; CLL-Associated Antigen KW-12; 60S Ribosomal Protein L11; DBA7; GIG34; L11.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSMAQDQGE KENPMRELRI RKLCLNICVG ESGDRLTRAA KVLEQLTGQT PVFSKARYTV RSFGIRRNEK IAVHCTVRGA KAEEILEKGL KVREYELRKN NFSDTGNFGF GIQEHIDLGI KYDPSIGIYG LDFYVVLGRP GFSIADKKRR TGCIGAKHRI SKEEAMRWFQ QKYDGIILPG K
Stability
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.
Formulation
The RPL11 solution (0.5mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.2M NaCl, 1mM DTT, 2mM EDTA, 250mM Imidazole and 50% glycerol.
